0069-0151 : Inlyta 5 mg Oral Tablet


NDC0069-0151
Labeler: Pfizer Laboratories Div Pfizer Inc
Product Type: Human Prescription Drug
Drug Name:  Inlyta
Dosage Form: Oral Tablet, Film Coated
Application #: NDA202324
Rev. Date: 


Appearance:


Markings: Pfizer;5;XNB
Shapes:  Triangle (3 sides)
Colors:  Red
Size (mm): 8
Segments: * 1

* Segments = the number of equally sized pieces which the pill can be broken into. In this case, a value of 1 indicates a solid pill with no score lines.

Pfizer 5 XNB: (0069-0151) Inlyta 5 mg Oral Tablet by Pfizer Laboratories Div Pfizer Inc
The above image is provided by the U.S. National Library of Medicine (NLM) and is not part of the official label.

NDC Package Codes:

  • 0069-0151-11: 60 TABLET, FILM COATED IN 1 BOTTLE (0069‑0151‑11)

Active Ingredients:

  • Axitinib

Dosage Strength:

  • 5 mg

Inactive Ingredients:

  • Cellulose, Microcrystalline
  • Lactose Monohydrate
  • Croscarmellose Sodium
  • Magnesium Stearate
  • Titanium Dioxide
  • Triacetin
  • Ferric Oxide Red
  • Hypromellose 2910 (15000 Mpa.s)

Pharmaceutical Classes:

  • Kinase Inhibitor [EPC]
  • Receptor Tyrosine Kinase Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 0069-0145 Inlyta 1 mg Oral Tablet by Pfizer Laboratories Div Pfizer Inc
  • 63539-026 Inlyta 1 mg Oral Tablet, Film Coated by U.S. Pharmaceuticals
  • 63539-044 Inlyta 5 mg Oral Tablet, Film Coated by U.S. Pharmaceuticals

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 0069-0151 QR Code

< Prev: 0069-0149Next: 0069-0152 >

Related Discussions:

axitinib
angiogenesis inhibitor...




Note: The MedsChat® NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.